[EN] METHOD FOR PREPARING (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES [FR] PROCÉDÉ D'ÉLABORATION DE DÉRIVÉS DE (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHÉNYL)-2-OXOOXAZOLIDIN-5-YL)MÉTHYL)THIOPHÈNE-2-CARBOXAMIDE
[EN] METHOD FOR PREPARING (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES [FR] PROCÉDÉ D'ÉLABORATION DE DÉRIVÉS DE (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHÉNYL)-2-OXOOXAZOLIDIN-5-YL)MÉTHYL)THIOPHÈNE-2-CARBOXAMIDE
Design, synthesis and structure–activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors
作者:Yanfang Zhao、Mingyan Jiang、Shunguang Zhou、Shasha Wu、Xiaolong Zhang、Longsheng Ma、Kai Zhang、Ping Gong
DOI:10.1016/j.ejmech.2015.04.025
日期:2015.5
A novel series of potent and efficacious factor Xa inhibitors which possesses pyrrole/indole/thiazole moieties as S4 binding element was identified. Compound 7b showed strong human factor Xa inhibitory activity (IC50 = 2.01 nM) and anticoagulant activities in both human (PTCT2 = 0.15 mu M, APPTCT(2) = 0.30 mu M) and rabbit plasma (PTCT2 = 0.46 mu M, APPTCT(2) = 0.75 mu M). The SARs analyses indicated that the size and water solubility of different alkylamino group at the position of S4 ligand were responsible for the anticoagulant activity. (C) 2015 Elsevier Masson SAS. All rights reserved.
METHOD FOR PREPARING (S)-5-CHLORO-N-((3-(4-(5,6-DIHYDRO-4H-1,2,4-OXADIAZIN-3-YL)PHENYL)-2-OXOOXAZOLIDIN-5-YL)METHYL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES
申请人:Cho Young Lag
公开号:US20120108808A1
公开(公告)日:2012-05-03
Provided is a method for preparing (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives of Formula (I) which are useful as blood coagulation factor Xa inhibitors, and said method using 1-fluoro-4-nitrobenzen as a starting material. According to the method of the present invention, (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives of Formula (I) which are useful as blood coagulation factor Xa inhibitors can be prepared in a high purity and a high yield.